The relationship of immune cell signatures to patient survival varies within and between tumor types

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Linsley, Peter S ^a   Chaussabel, Damien ^a   Speake, Cate ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COLON ADENOCARCINOMA; CONTROLLED STUDY; CUTANEOUS MELANOMA; CYSTADENOCARCINOMA; DISEASE MARKER; ENDOMETRIUM CARCINOMA; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; NATURAL KILLER CELL; NEUTROPHIL; RECTUM CARCINOMA; RNA SEQUENCE; SEQUENCE ALIGNMENT; SQUAMOUS CELL LUNG CARCINOMA; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNITY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MORTALITY; NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; RNA; TRANSCRIPTOME; TUMOR MARKER;

BIOMARKERS, TUMOR; FMS-LIKE TYROSINE KINASE 3; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MYELOID CELLS; NEOPLASMS; PROGNOSIS; RNA, NEOPLASM; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSCRIPTOME;

EID: 84946934928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138726     Document Type: Article

References (51)

1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39: 1-10. doi: 10.1016/j.immuni.2013.07.012 PMID: 23890059
2. Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature. 2014; 515: 496-498. doi: 10.1038/515496a PMID: 25428495
3. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450: 903-907. doi: 10.1038/nature06309 PMID: 18026089
4. Acharya UH, Jeter JM. Use of ipilimumab in the treatment of melanoma. Clin Pharmacol Adv Appl. 2013; 5: 21-27. doi: 10.2147/CPAA.S45884
5. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011; 9: 204. doi: 10.1186/1479-5876-9-204 PMID: 22123319
6. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515: 568-571. doi: 10.1038/nature13954 PMID: 25428505
7. Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563-567. doi: 10.1038/nature14011 PMID: 25428504
8. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 1960-1964. doi: 10.1126/science.1129139 PMID: 17008531
9. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348: 203-213. doi: 10. 1056/NEJMoa020177 PMID: 12529460
10. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013; 39: 11-26. doi: 10.1016/j.immuni.2013. 07.008 PMID: 23890060
11. Pagès F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautès-Fridman C, Fridman W-H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 29: 1093-1102. doi: 10.1038/onc.2009.416 PMID: 19946335
12. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2014; 20: 5064-5074. doi: 10.1158/1078-0432.CCR-13-3271
13. Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. with Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45: 1113-1120. doi: 10.1038/ng.2764 PMID: 24071849
14. Benz CC, Perou CM, Stuart JM with Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al., Cancer Genome Atlas Research Network. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158: 929-944. doi: 10.1016/j. cell.2014.06.049 PMID: 25109877
15. Linsley PS, Speake C, Whalen E, Chaussabel D. Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis. PloS One. 2014; 9: e109760. doi: 10.1371/journal.pone.0109760 PMID: 25314013
16. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008; 29: 150-164. doi: 10.1016/j.immuni.2008.05.012 PMID: 18631455
17. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011; 144: 296-309. doi: 10.1016/j.cell.2011.01.004 PMID: 21241896
18. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol. 2014; 15: 195-204. doi: 10.1038/ni.2789 PMID: 24336226
19. Therneau T. A Package for Survival Analysis in S. R package version 2.37-4 [Internet]. Available: http://CRAN.R-project.org/package=survival
20. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004; 23: 2109-2123. doi: 10.1002/sim.1802 PMID: 15211606
21. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387. doi: 10. 1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 PMID: 8668867
22. Galluzzi L, Vacchelli E, Pedro J-MB-S, Buqué A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014; 5: 12472-12508. PMID: 25537519
23. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al., TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res Off J Am Assoc Cancer Res. 2007; 13: 3207-3214. doi: 10.1158/1078-0432.CCR-06-2765
24. Beck AH, Knoblauch NW, Hefti MM, Kaplan J, Schnitt SJ, Culhane AC, et al. Significance analysis of prognostic signatures. PLoS Comput Biol. 2013; 9: e1002875. doi: 10.1371/journal.pcbi.1002875 PMID: 23365551
25. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol. 2011; 7: e1002240. doi: 10.1371/journal.pcbi.1002240 PMID: 22028643
26. Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014; 6: 228ra37. doi: 10.1126/scitranslmed.3007240 PMID: 24648340
27. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515: 558-562. doi: 10.1038/nature13904 PMID: 25428503
28. Zlotnik A, Yoshie O. The Chemokine Superfamily Revisited. Immunity. 2012; 36: 705-716. doi: 10. 1016/j.immuni.2012.05.008 PMID: 22633458
29. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004; 4: 540-550. doi: 10.1038/nrc1388 PMID: 15229479
30. Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmström P-U, Tötterman TH. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol. 2007; 177: 353-358. doi: 10.1016/j.juro.2006.08.078 PMID: 17162090
31. Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. Science. 2011; 331: 1565-1570. doi: 10.1126/science.1203486 PMID: 21436444
32. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010; 21: 409-414. doi: 10.1093/annonc/mdp325
33. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354: 709-718. doi: 10.1056/NEJMoa053007 PMID: 16481638
34. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45: 1127-1133. doi: 10.1038/ng.2762 PMID: 24071851
35. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The Somatic Genomic Landscape of Glioblastoma. Cell. 2013; 155: 462-477. doi: 10.1016/j.cell.2013.09.034 PMID: 24120142
36. Minárik I, Laštovicka J, Budinský V, Kayserová J, Spíšek R, Jarolím L, et al. Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma. Immunol Lett. 2013; 152: 144-150. doi: 10.1016/j.imlet.2013.05.010 PMID: 23721909
37. Keskin S, Keskin Z, Taskapu HH, Kalkan H, Kaynar M, Poyraz N, et al. Prognostic value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and multiphasic renal tomography findings in histological subtypes of renal cell carcinoma. BMC Urol. 2014; 14. doi: 10.1186/1471-2490-14-95
38. Balkwill FR. The chemokine system and cancer. J Pathol. 2012; 226: 148-157. doi: 10.1002/path.3029 PMID: 21989643
39. Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, et al. Aire-dependent thymic development of tumor-associated regulatory T cells. Science. 2013; 339: 1219-1224. doi: 10.1126/science. 1233913 PMID: 23471412
40. Rotondo R, Bertolotto M, Barisione G, Astigiano S, Mandruzzato S, Ottonello L, et al. Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol. 2011; 89: 721-727. doi: 10.1189/jlb.1109737 PMID: 21330347
41. Jacobs JFM, Nierkens S, Figdor CG, de Vries IJM, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012; 13: e32-42. doi: 10.1016/S1470-2045(11)70155-3 PMID: 22225723
42. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12: 323. doi: 10.1186/1471-2105-12-323 PMID: 21816040
43. Shay T, Jojic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, Feng T, et al., ImmGen Consortium. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc Natl Acad Sci U S A. 2013; 110: 2946-2951. doi: 10.1073/pnas.1222738110 PMID: 23382184
44. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: proteinprotein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013; 41: D808-815. doi: 10.1093/nar/gks1094 PMID: 23203871
45. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13: 2498-2504. doi: 10.1101/gr.1239303 PMID: 14597658
46. Montojo J, Zuberi K, Rodriguez H, Bader GD, Morris Q. GeneMANIA: Fast gene network construction and function prediction for Cytoscape. F1000Research. 2014; 3: 153. doi: 10.12688/f1000research. 4572.1 PMID: 25254104
47. R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing [Internet]. Vienna, Austria.; 2013. Available: http://www.R-project.org
48. Wickham H. ggplot2: elegant graphics for data analysis. [Internet]. 2009. Available: http://had.co.nz/ggplot2/book
49. Wickham H. Reshaping Data with the reshape Package. J Stat Softw. 2007; 21: 1-20.
50. Terry M. Therneau, Grambsch Patricia M. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
51. Abhijit, Thomas G, Cowley M. An enhanced Kaplan-Meier plot [Internet]. 2011. Available: http://www.rbloggers. com/an-enhanced-kaplan-meier-plot/